

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (cancelled).

Claim 2 (previously amended): A cell expressing gamma-aminobutyric acid (GABA) isolated from a human NT2 cell line, wherein the cell comprises a cell deposited with the American Type Culture Collection (ATCC) Manassas, Virginia (USA), under Designation No. PTA-7154 .

Claim 3 (cancelled).

Claim 4 (previously amended): A cell expressing gamma-aminobutyric acid (GABA) cloned from a human NT2 cell line.

Appl. No.: 10/553,291
Amendment After Final Rejection dated September 16, 2008
Reply to Office Action (Final Rejection) of September 4, 2008

Claims 5-8 (cancelled).

Claim 9 (previously amended): A method of treating a neurological disease, condition, or disorder, comprising:

transplanting in a subject in need thereof a suitable amount of gamma-aminobutyric acid (GABA) expressing hNT2 cells cloned from a human NT2 cell line, in or adjacent to the spinal cord of the subject.

Claims 10-27 (cancelled).

Claim 28 (original): The cell of Claim 4, wherein:

the cell comprises a cell deposited with the American Type Culture Collection (ATCC) Manassas, Virginia (USA), under Designation No. PTA-7154.

Claims 29-31 (cancelled).